Women represent half of the planet's population, and still, there is limited investment in technologies addressing health conditions affecting women. The majority of clinical testing and trials during the product development stages do not consider women's health and needs. We have very little cellular and molecular understanding of many women's health conditions, partly due to the high morbidity and low mortality associated with these diseases. We have developed organoids from healthy and abnormal human reproductive organs and showed their utility in understanding the complex pathobiology of gynaecological diseases. By applying next generation seq and scRNA seq, we have defined how different subpopulations of cells change during the transition from healthy to disease state. The current work is focussed on utilising these patient-derived models to guide treatments in the clinic.